Sexual consequences of multiple sclerosis and other central nervous system disorders

2015 ◽  
pp. 741-746
Author(s):  
Maarten Albersen ◽  
Dirk De Ridder
Author(s):  
Emilie Audouard ◽  
Lisa Rousselot ◽  
Marc Folcher ◽  
Nathalie Cartier ◽  
Françoise Piguet

Improving a drug delivery system is critical to treat central nervous system disorders. Here we studied an innovative approach based on implantation of a wireless-powered cell-based device in mice. This device, coupling biologic material and electronics, is the first of its kind. The advantage of this technology is its ability to control the secretion of a therapeutic molecule and to switch the classical permanent delivery to activation on demand. In diseases with relapsing-remitting phases such as multiple sclerosis, such activation could be selectively achieved in relapsing phases. However, the safety (tolerance to biomaterials and surgical procedure) of such a clinical device needs to be verified. Therefore, the development of tools to assess the biocompatibility of the system in animal models is an essential step. We present the development of this new therapeutic approach, the challenges we encountered during the different steps of its development (such as cell loading in the chamber, surgery protocol for subcutaneous implantation of the device) and the tools we used to evaluate cell viability and biocompatibility of the device.


2015 ◽  
Vol 22 (7) ◽  
pp. 964-968 ◽  
Author(s):  
Sasitorn Siritho ◽  
Douglas K Sato ◽  
Kimihiko Kaneko ◽  
Kazuo Fujihara ◽  
Naraporn Prayoonwiwat

Background: Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients. Objectives: To describe clinical phenotypes associated with anti-MOG. Methods: Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG. Results: Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment. Conclusions: Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.


2016 ◽  
Vol 31 (1) ◽  
pp. 23-33 ◽  
Author(s):  
Meizhen Huang ◽  
Lin-Rong Liao ◽  
Marco YC Pang

Objectives: To examine the effects of whole-body vibration on spasticity among people with central nervous system disorders. Methods: Electronic searches were conducted using CINAHL, Cochrane Library, MEDLINE, Physiotherapy Evidence Database, PubMed, PsycINFO, SPORTDiscus and Scopus to identify randomized controlled trials that investigated the effect of whole-body vibration on spasticity among people with central nervous system disorders (last search in August 2015). The methodological quality and level of evidence were rated using the PEDro scale and guidelines set by the Oxford Centre for Evidence-Based Medicine. Results: Nine trials with totally 266 subjects (three in cerebral palsy, one in multiple sclerosis, one in spinocerebellar ataxia, and four in stroke) fulfilled all selection criteria. One study was level 1b (PEDro⩾6 and sample size>50) and eight were level 2b (PEDro<6 or sample size ⩽50). All three cerebral palsy trials (level 2b) reported some beneficial effects of whole-body vibration on reducing leg muscle spasticity. Otherwise, the results revealed no consistent benefits on spasticity in other neurological conditions studied. There is little evidence that change in spasticity was related to change in functional performance. The optimal protocol could not be identified. Many reviewed studies were limited by weak methodological and reporting quality. Adverse events were minor and rare. Conclusion: Whole-body vibration may be useful in reducing leg muscle spasticity in cerebral palsy but this needs to be verified by future high quality trials. There is insufficient evidence to support or refute the notion that whole-body vibration can reduce spasticity in stroke, spinocerebellar ataxia or multiple sclerosis.


2021 ◽  
pp. 026921552110184
Author(s):  
Rita Lenoir dit Caron ◽  
Jeremy Coquart ◽  
Maxime Gilliaux

Objective: Investigate the effect of yoga on health-related quality of life (HRQoL) in patients with central nervous system disorders. Methods: A systematic search was conducted on the PubMed-NCBI, EBSCO Host, Cochrane Library, Scopus and ScienceDirect databases until 05 April 2021. Only randomized control trials published in English or French were included and had to compare yoga to another intervention group or a control group. They also had to clearly measure HRQoL. Methodological quality was assessed with the revised Cochrane risk-of-bias tool for randomized trials and the quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Results: Sixteen studies were found, including six for multiple sclerosis, five for Parkinson’s disease, two for stroke, one for dementia, one for epilepsy and one for brain tumour. Only 12 studies performed between-group statistics and 8 found a significant difference between groups after treatment. When yoga was compared to no intervention, the results were generally in favour of the yoga group, but when yoga was compared to another intervention programme, there was generally no significant difference between groups. There were many different HRQoL questionnaires, even within the same disease, which reduces the comparability of studies. Conclusions: With low to moderate quality of the evidence, yoga seems effective to improve HRQoL in people with Parkinson’s disease. For multiple sclerosis, stroke, dementia, epilepsy and brain tumour, the quality of the evidence is still insufficient to conclude of the effectiveness of yoga.


1997 ◽  
Vol 78 (3) ◽  
pp. 238-238
Author(s):  
B. G. Sadykov

In Kazan, three practical manuals "Extragenital Pathology and Pregnancy" edited by Professor Z.Sh. Gilyazutdinova, Honored Scientist and Laureate of the State Prize of the Republic of Tatarstan, have been published. These works cover the most serious types of complications accompanying pregnancy, diseases of the cardiovascular and urinary systems, viral hepatitis, central nervous system disorders (syringomyelia, epilepsy, myasthenia, multiple sclerosis), as well as diabetes mellitus and thyroid disease.


2007 ◽  
Author(s):  
P. S. Seibert ◽  
P. D. Parker ◽  
C. M. Patterson ◽  
N. Whitener ◽  
J. O'Donnell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document